Author/Authors :
Zaree، Mina نويسنده Department of Biochemistry and Clinical Laboratories, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran , , Shahnazi، Vahideh نويسنده , , Fayezi، Shabnam نويسنده Students Research Committee, Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran , , Darabi، Maryam نويسنده Department of Biochemistry and Genetics, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran , , Mehrzad Sadaghiani، Mahzad نويسنده Alzahra Hospital, Infertility and IVF Center, Tabriz University of Medical Sciences, Tabriz, Iran , , Darabi، Masoud نويسنده Department of Biochemistry and Clinical Laboratories, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran , , Khani، Sajjad نويسنده Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran , , Nouri، Mohammad نويسنده Women’s Reproductive Health Research Center, Alzahra Hospital, Tabriz University of Medical Sciences, Tabriz, Iran ,
Abstract :
Background: The omega-3 fatty acid (?-3 fatty acid) such as eicosapentaenoic acid
(EPA) is currently used in the clinic as a nutritional supplement in the treatment of polycystic
ovarian syndrome (PCOS). The present study was designed to investigate the effect
of EPA on the expression levels of peroxisome proliferator-activated receptor gamma
(PPAR?) and cytochrome P450 aromatase (encoded by the CYP-19) in primary cultured
granulosa cells (GC) from patients undergoing in vitro fertilization (IVF), and also to
compare these effects with those in GC of PCOS patients.
Materials and Methods: In this experimental study, human GC were isolated, primary
cultured in vitro, exposed to a range of concentrations of the EPA and investigated
with respect to gene expression levels of PPAR? and CYP-19 using real
time-polymerase chain reaction (PCR). The participants (n=30) were the patients
admitted to the IVF Center in February-March 2013 at Alzahra Hospital, Tabriz,
Iran, who were divided into two groups as PCOS (n=15) and non-PCOS (n=15)
women (controls).
Results: All doses of the EPA significantly induced PPAR? mRNA gene expression level
as compared to the control recombinant follicle stimulating hormone (rFSH) alone condition.
High doses of EPA in the presence of rFSH produced a stimulatory effect on expression
level of PPAR? (2.15-fold, P=0.001) and a suppressive effect (0.56-fold, P=0.01) on
the expression level of CYP-19, only in the PCOS GC.
Conclusion: EPA and FSH signaling pathway affect differentially on the gene expression
levels of PPAR? and CYP-19 in PCOS GC. Altered FSH-induced PPAR?
activity in PCOS GC may modulate the CYP-19 gene expression in response to EPA,
and possibly modulates the subsequent steroidogenesis of these cells.
